Domino Effect: Teva withdraws patent application in India after USPTO invalidates its patent in blockbuster drug COPAXONE
In a groundbreaking development, Israeli behemoth Teva Pharmaceutical Industries Ltd. (Teva) has suffered a third consecutive blow after the US Patent Office (USPTO) invalidated its third patent [U.S. Patent No. 8,969,302] for COPAXONE (Glatiramer Acetate) on September 1, 2016. According to The Financial Express, the USPTO upheld a Mylan’s challenge in an Inter-partes Review (IPR) and found that all claims in the said COPAXONE patent were un-patentable. The 40mg version of COPAXONE is a $4 billion blockbuster injectable drug used […]